Zobrazeno 1 - 10
of 19
pro vyhledávání: '"L R Laufman"'
Publikováno v:
Annals of Oncology. 10:989-991
Summary Purpose To evaluate the efficacy of a novel multiday schedule of vinorelbine and cisplatin in patients with advanced NSCLC. Patients and methods Thirty patients were enrolled, including 27 patients with stage IV disease, and 11 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e5a1c678014ca47f74d8a78fb8df38
https://doi.org/10.1023/a:1008355504913
https://doi.org/10.1023/a:1008355504913
Autor:
J. Pritchard, T. Patel, T. Moore, L. R. Laufman, J. Jones, D. Colborn, J. Zangmeister, C. H. Spiridonidis, J. P. Kuebler, N. Larrimer, L. Carman, R. Roach, L. Gutterman, M. Segal
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(9)
sColumbus Community Clinical Oncology Program, Columbus. Ohio, USA Summary Background Docetaxel and gemcitabine are active against breast cancer. The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c77fa46eb196f4f8872a3b411add6a
https://pubmed.ncbi.nlm.nih.gov/11697837
https://pubmed.ncbi.nlm.nih.gov/11697837
Autor:
R. Roach, L. Carman, Ch. George, R. Rupert, L. R. Laufman, J.Ph. Kuebler, C. H. Spiridonidis, T. Patel, Timothy Moore, J. Jones, S. Blair, D. Colborn, J. Zangmeister
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(1)
Summary Background Docetaxel and gemcitabine are active against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of monthly docetaxel combined with weekly gemcitabi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5788d7eb57baaae53528203082876c3b
https://pubmed.ncbi.nlm.nih.gov/11249055
https://pubmed.ncbi.nlm.nih.gov/11249055
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 16(12)
PURPOSE To determine the maximum-tolerated dose of monthly docetaxel combined with fixed-dose weekly gemcitabine and describe the dose-limiting toxicities (DLTs) of the combination. PATIENTS AND METHODS Patients with refractory solid tumors were trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dba7f89c8ed02d19b378cdcc7499feed
https://pubmed.ncbi.nlm.nih.gov/9850032
https://pubmed.ncbi.nlm.nih.gov/9850032
Autor:
P N, Grozea, J J, Crowley, V A, Canfield, L, Kingsbury, S W, Ross, G S, Beltran, L R, Laufman, G R, Weiss, R B, Livingston
Publikováno v:
Cancer. 80(6)
Teniposide (VM-26) was reported to have activity in small cell lung carcinoma (SCLC). The authors performed a Phase II study of teniposide as a treatment for patients with previously untreated extensive SCLC.The study was open to patients with a hist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9288200fa966e0534f4f9bf5e1769e52
https://pubmed.ncbi.nlm.nih.gov/9486592
https://pubmed.ncbi.nlm.nih.gov/9486592
Publikováno v:
Cancer. 78(10)
In patients with advanced esophageal adenocarcinoma, the efficacy and palliative role of systemic chemotherapy are not well defined. The primary objective of this Phase II trial was to evaluate the antitumor activity and toxicity of a multiday chemot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::63af60c51992c3272e71792ac1067243
https://pubmed.ncbi.nlm.nih.gov/8918399
https://pubmed.ncbi.nlm.nih.gov/8918399
Autor:
C H, Spiridonidis, L R, Laufman, K A, Stydnicki, J W, Noltimier, C C, Cho, D C, Young, W J, Hicks, M L, Segal, J T, Guy, B L, Zidar
Publikováno v:
Cancer. 75(7)
The assessment of treatment efficacy in nonsmall cell lung cancer (NSCLC) is limited by the lack of a clear association between clinical response and survival. The prognostic usefulness of treatment-induced tumor-marker declines in NSCLC has not been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4803eab10492b90552580bf09f65a998
https://pubmed.ncbi.nlm.nih.gov/8826914
https://pubmed.ncbi.nlm.nih.gov/8826914
Publikováno v:
Cancer. 75(3)
Multiple myeloma is considered to be a drug responsive disease; however, there is no cure for this disease and virtually all patients will develop drug resistance. One form of drug resistance that has been documented is the multidrug resistance pheno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e1ca1ee8270fb684b45c064e9e177aa9
https://pubmed.ncbi.nlm.nih.gov/7828131
https://pubmed.ncbi.nlm.nih.gov/7828131
Publikováno v:
Anti-cancer drugs. 5(2)
Didemnin B is a cyclic peptide isolated from the marine tunicate Trididemnin cyanophorum. It is a known potent inhibitor of RNA, DNA and protein synthesis, with activity against the murine B16 melanoma. Fourteen patients with disseminated malignant m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f3ea0242e3ad5203f3d0015cd3b8427
https://pubmed.ncbi.nlm.nih.gov/8049497
https://pubmed.ncbi.nlm.nih.gov/8049497
Autor:
R M Bukowski, L R Laufman, W D Brenckman, N J Clendennin, M A Collier, B A Sullivan, A Guaspari, R A McKinnis
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(10)
PURPOSE A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer. PATIENTS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12ded0f4040a1720c22a921b93562191
https://pubmed.ncbi.nlm.nih.gov/8410114
https://pubmed.ncbi.nlm.nih.gov/8410114